Skip to content

CircOGDH as a biomarker of the ischemic penumbra in acute ischemic stroke: a case-control study

CircOGDH as a biomarker of the ischemic penumbra in acute ischemic stroke: a case-control study

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100046260
Enrollment
Unknown
Registered
2021-05-12
Start date
2021-05-08
Completion date
Unknown
Last updated
2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic stroke

Interventions

the&#32
expression&#32
of&#32
CircoGDH&#32
in&#32
&#32
used&#32
to&#32
Gold Standard:According to the 2018 Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke: 1. Acute onset
2. Defect of meridian function of kitchen god
3. Imaging lesions or symptoms/signs lasting more than 24 hours
4. Exclude non-vascular etiology
5. Brain CT/MRI to exclude bleeding.
Index test:1.&#32
quantitative&#32
was&#32

Sponsors

The First Affiliated Hospital of Jinan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Control group: 1. Aged >=18 years; 2. Normal neurological physical examination; 3. patients or their family signed informed consent. Acute cerebral infarction group: 1. Aged >=18 years; 2. Acute cerebral infarction (onset <=24h); 3. Cerebral infarction confirmed by cranial MRI; 4. First stroke, or previous stroke history, but the pre-onset MRS score <=1; 5. Meet the following diagnostic criteria: According to the 2018 Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke: (1)Acute onset; (2)Neurological function deficit ; (3)Imaging lesions or symptoms/signs lasting more than 24 hours; (4)Exclude non-vascular etiology; (5)Brain CT/MRI to exclude bleeding. 6. Patients or their family signed informed consent.

Exclusion criteria

Exclusion criteria: Control group: Previous history of stroke, severe cardiopulmonary, hepatic and renal insufficiency, other serious underlying diseases such as myocardial infarction, blood disease, peripheral vascular disease or other thrombotic diseases. Acute cerebral infarction group: 1. Patients with incomplete clinical data, non-stroke death and lost to follow-up; 2. Transvenous thrombolysis and mechanical thrombectomy; 3. Previous history of severe cardiopulmonary, hepatic and renal insufficiency, other serious underlying diseases such as myocardial infarction, blood disease, peripheral vascular disease or other thrombotic diseases; 4. Patients with dementia, Parkinson's disease, tumor, epilepsy, mental illness, etc.; 5. Patients with neurological impairment or loss caused by other non-vascular causes, such as brain trauma, subdural hematoma, brain tumor, etc.

Design outcomes

Primary

MeasureTime frame
CircOGDH expression level in plasma;Size of ischemic penumbra;

Countries

China

Contacts

Public ContactXu Anding

The First Affiliated Hospital of Jinan University

tlil@jnu.edu.cn+86 13392692160

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026